Glucose Health (OTCMKTS:GLUC) Stock Price Down 13.7% – Here’s What Happened

Glucose Health, Inc. (OTCMKTS:GLUC) fell 13.7% during trading on Thursday . The company traded as low as $0.39 and last traded at $0.4143. 29,379 shares were traded during trading, a decline of 5% from the average session volume of 30,786 shares. The stock had previously closed at $0.4798.

Key Glucose Health News

Here are the key news stories impacting Glucose Health this week:

• Positive Sentiment: Industry leaders (Dexcom, Insulet, Abbott) are highlighting CGM benefits and pushing into type 2 diabetes, supporting broader CGM adoption and market expansion. Insulet, Abbott, Dexcom set sights on Type 2 diabetes at ATTD
• Positive Sentiment: Dexcom previewed long‑term health benefits of CGMs for diabetics, reinforcing clinical value that can drive device adoption and recurring revenue models. Dexcom gives sneak preview of CGM technologies’ long-term health benefits for diabetics
• Positive Sentiment: New research (Ultrahuman/Stanford) links consistent sleep timing to improved glucose control — the kind of lifestyle data that can increase consumer interest in continuous monitoring. Ultrahuman study shows sleep timing is a secret lever for glucose control
• Positive Sentiment: Public-health reporting shows calls for earlier diabetes screening as youth cases rise, which could expand the addressable market for monitoring and digital health services. Experts call for early diabetes checks as youth cases rise
• Neutral Sentiment: Studies linking psychiatric diagnoses and psychotropic drugs to obesity/diabetes risk highlight unmet screening needs; could be opportunity or regulatory/clinical scrutiny. Studies Link Psychiatric Labels and Drugs to Obesity and Diabetes Risk Factors, Yet Screening Falls Short
• Neutral Sentiment: Researchers report a saliva test that detects hidden diabetes risk — a potential complementary screening tool but not an immediate CGM replacement. Scientists Discover Simple Saliva Test That Reveals Hidden Diabetes Risk
• Neutral Sentiment: Consumer stories and nutrition pieces (apples, berries, diet soda, ice cream) keep public interest in blood‑sugar management high but are low impact for near‑term stock moves. Are apples safe for people with diabetes?
• Negative Sentiment: Recent recalls and safety alarms around wearable glucose monitors (reports linking an Abbott recall to deaths) are rattling users and regulators—this raises short‑term sector risk and could depress sentiment and device uptake. Diabetics who rely on glucose monitors are alarmed by recall linked to 7 deaths
• Negative Sentiment: Guides cautioning consumers after wearable CGM recalls increase short‑term uncertainty and may slow adoption until safety/regulatory clarity returns. What you should know about wearable glucose monitors in wake of recall

Glucose Health Price Performance

The company has a market cap of $8.39 million, a P/E ratio of -13.67 and a beta of 1.26. The firm’s 50-day moving average is $0.32 and its two-hundred day moving average is $0.18.

Glucose Health Company Profile

Glucose Health, Inc engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc in November 2014. Glucose Health, Inc was incorporated in 2007 and is based in Bentonville, Arkansas.